Search

Wojciech J Ardelt

from New City, NY
Age ~87
Get Report
Also known as:
Wojciech Y Ardelt, Wojciech B Ardelt, Woyciech Y Ardelt, Wojcieck K Ardelt, Wojci Ardelt, Wojcjech Ardelt
Phone and address:
8 Prides Xing, New City, NY 10956
(845) 639-9733
Related to:
Clarence J PlacekMagdalena E Ardelt, 48Agnieszka A Ardelt, 57Piotr Kulesza Ardelt, 57Barbara K Ardelt, 87Peter Kulesza, 57
Connected to:
Barry N Arden, 61Brant M Arden, 38Celia L Arden, 90Clara A Arden, 76Destany A Arden, 44Emilia Arden, 65Janelle L Arden, 61Jeffrey A Arden, 51Jennifer Arden, 45Josh Arden, 35

Wojciech Ardelt Phones & Addresses

  • 8 Prides Xing, New City, NY 10956 (845) 639-9733
  • Bridgewater, NJ
  • West Lafayette, IN
  • West Nyack, NY
  • Somerset, NJ

Work

Company: Alfacell Position: Director of biochemistry

Education

Degree: Graduate or professional degree

Industries

Biotechnology

Resumes

Resumes

Wojciech Ardelt Photo 1

Wojciech Ardelt

View page
Location:
New City, NY
Industry:
Biotechnology
Work:
Alfacell
Director of Biochemistry

Publications

Us Patents

Mutant Form Of A Cytotoxic Ribonucleolytic Protein Which Allows Production By Recombinant Methods

View page
US Patent:
6649392, Nov 18, 2003
Filed:
Apr 4, 1996
Appl. No.:
08/626288
Inventors:
Richard J. Youle - Bethesda MD
Veena M. Vasandani - Rockville MD
Ester Boix - Barcelona, ES
Wojciech Ardelt - New City NY
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C12N 922
US Classification:
435199, 536 232, 536 231
Abstract:
The present invention provides recombinant Onc (rOnc) compositions and methods. Recombinant Onc proteins of the invention have an amino terminal methionine and comprise an Onc polypeptide. The amino terminal methionine of the protein allows for recombinant production in a bacterial host cell. Cleaving the amino terminal methionine exposes the amino terminal glutamine of the polypeptide. The Onc polypeptide has an amino terminal glutamine. Cyclization of the amino terminal glutamine of the polypeptide to a pyroglutamyl residue provides rOnc polypeptides and proteins have anti-cancer and anti-viral activity.

Mutant Form Of Cytotoxic Ribonucleolytic Protein Which Allows Production By Recombinant Methods

View page
US Patent:
6649393, Nov 18, 2003
Filed:
Jun 10, 1998
Appl. No.:
09/095429
Inventors:
Richard J. Youle - Bethesda MD
Veena M. Vasandani - Rockville MD
Ester Boix - Barcelona, ES
Wojciech Ardelt - New City NY
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C12N 922
US Classification:
435199, 43525233, 4353201, 536 232, 536 231, 536 235
Abstract:
The present invention provides recombinant Onc (rOnc) compositions and methods. Recombinant Onc proteins of the invention have an amino terminal methionine and comprise an Onc polypeptide. The amino terminal methionine of the protein allows for recombinant production in a bacterial host cell. Cleaving the amino terminal methionine exposes the amino terminal glutamine of the polypeptide. The Onc polypeptide has an amino terminal glutamine. Cyclization of the amino terminal glutamine of the polypeptide to a pyroglutamyl residue provides rOnc polypeptides and proteins have anti-cancer and anti-viral activity.

Methods Of Treating Infections Originating From Viruses In The Herpesviridae Family

View page
US Patent:
8518399, Aug 27, 2013
Filed:
Nov 17, 2010
Appl. No.:
12/948026
Inventors:
Shailendra K. Saxena - Monroe Township NJ, US
Wojciech Ardelt - New City NY, US
Assignee:
Tamir Biotechnology, Inc. - San Diego CA
International Classification:
A61K 38/46
US Classification:
424 946
Abstract:
Three RNases (ranpirnase, the second embodiment disclosed in U. S. Pat. No. 5,728,805, and recombinant Amphinase-2) are tested against identified herpesviridae infections. With some exceptions, quantitative PCR assays indicate that the RNases have anti-viral activity against many of these viruses.

Methods Of Treating Kaposi's Sarcoma

View page
US Patent:
20140030246, Jan 30, 2014
Filed:
Jul 26, 2013
Appl. No.:
13/952211
Inventors:
Wojciech ARDELT - NEW CITY NY, US
Assignee:
Tamir Biotechnology, Inc. - San Diego CA
International Classification:
A61K 38/46
US Classification:
424 946
Abstract:
Three RNases (ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2) are tested against identified herpesviridae infections. With some exceptions, quantitative PCR assays indicate that the RNases have anti-viral activity against many of these viruses.

Methods Of Treating Infections Originating From Viruses In The Herpesviridae Family

View page
US Patent:
20140037610, Feb 6, 2014
Filed:
Jul 26, 2013
Appl. No.:
13/952326
Inventors:
Wojciech ARDELT - NEW CITY NY, US
Assignee:
Tamir Biotechnology, Inc. - San Diego CA
International Classification:
A61K 38/46
US Classification:
424 946
Abstract:
Three RNases (ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2) are tested against identified herpesviridae infections. With some exceptions, quantitative PCR assays indicate that the RNases have anti-viral activity against many of these viruses.

Compositions Comprising Onconase (Tm) And Stelazine (Tm) Or Tamoxifen (Tm)

View page
US Patent:
55409253, Jul 30, 1996
Filed:
Aug 1, 1994
Appl. No.:
8/283969
Inventors:
Stanislaw M. Mikulski - Essex Fells NJ
Wojciech J. Ardelt - Passaic NJ
Assignee:
Alfacell Corporation - Bloomfield NJ
International Classification:
A61K 3843
C12N 922
US Classification:
424 946
Abstract:
A pharmaceutical to be sold under the ONCONASE trademark, as described in pending commonly owned application application Ser. No. 07/436,141 filed Nov. 13, 1989 is combined with other drugs sold under the trademarks TAMOXIFEN and STELAZINE. The combination of ONCONASE with TAMOXIFEN has unexpected bioactivity in vitro against ASPC-1 human pancreatic adenocarcinoma cells and the combination of ONCONASE with STELAZINE has unexpected bioactivity in vitro against A-549 human lung carcinoma cells.

Frog Embryo And Egg-Derived Tumor Cell Anti-Proliferation Protein

View page
US Patent:
55592120, Sep 24, 1996
Filed:
Aug 1, 1994
Appl. No.:
8/283970
Inventors:
Wojciech J. Ardelt - Passaic NJ
Assignee:
Alfacell Corporation - Bloomfield NJ
International Classification:
C07K 14475
US Classification:
530350
Abstract:
Rana pipiens eggs are subjected to fertilization and the embryos are grown to a predetermined stage of development. The embryos and unfertilized eggs are then subjected to mechanical processing in the presence of a weakly acidic buffer to produce an extract. The extract is subjected to ion-exchange chromatography and size-exclusion chromatography. The resulting pharmaceutical has activity against certain cancer cells. The amino acid sequence and composition of the pharmaceutical are disclosed.

Pharmaceutical For Treating Tumors And Method For Making It

View page
US Patent:
48824216, Nov 21, 1989
Filed:
Apr 6, 1988
Appl. No.:
7/178118
Inventors:
Kuslima Shogen - Somerset NJ
Stanislaw M. Mikulski - Essex Fells NJ
Wojciech J. Ardelt - Passaic NJ
Assignee:
Alfacell Corporation - Bloomfield NJ
International Classification:
C07K 302
C07K 312
US Classification:
530350
Abstract:
Rana pipiens eggs are subjected to fertilization and the embryos are grown to a predetermined stage of development. The embryos and unfertilized eggs are then subjected to mechanical processing in the presence of a weakly acidic buffer to produce an extract. The extract is subjected to ion-exchange chromatography and size-exclusion chromatography. The resulting pharmaceutical has activity against certain cancer cells. A partial amino acid sequence of the pharmaceutical is disclosed.
Control profile
Wojciech J Ardelt from New City, NY, age ~87 Get Report